CKAP2

Summary

CKAP2 (cytoskeleton associated protein 2, HGNC:1990) is a protein-coding gene on chromosome 13q14.3, encoding Cytoskeleton-associated protein 2 (Q8WWK9). Possesses microtubule stabilizing properties.

This gene encodes a cytoskeleton-associated protein that stabalizes microtubules and plays a role in the regulation of cell division. The encoded protein is itself regulated through phosphorylation at multiple serine and threonine residues. There is a pseudogene of this gene on chromosome 14. Alternative splicing results in multiple transcript variations.

Source: NCBI Gene 26586 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 105 total — 1 pathogenic
• MANE Select transcript: NM_018204

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1990
Approved symbol	CKAP2
Name	cytoskeleton associated protein 2
Location	13q14.3
Locus type	gene with protein product
Status	Approved
Aliases	LB1, FLJ10749, se20-10, TMAP
Ensembl gene	ENSG00000136108
Ensembl biotype	protein_coding
OMIM	611569
Entrez	26586

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 9 protein_coding, 1 retained_intron

ENST00000258607, ENST00000378034, ENST00000378037, ENST00000459902, ENST00000468284, ENST00000480747, ENST00000490903, ENST00000898697, ENST00000898698, ENST00000898699

RefSeq mRNA: 4 — MANE Select: NM_018204 NM_001098525, NM_001286686, NM_001286687, NM_018204

CCDS: CCDS41893, CCDS66557, CCDS73578, CCDS9435

Canonical transcript exons

ENST00000258607 — 9 exons

Exon	Start	End
ENSE00000923580	52461058	52461926
ENSE00000923581	52462363	52462567
ENSE00000923582	52465295	52465465
ENSE00000923583	52468278	52468347
ENSE00000923584	52473829	52474084
ENSE00000939602	52460899	52460974
ENSE00003659399	52456523	52456607
ENSE00003845744	52455478	52455626
ENSE00003850705	52474895	52476627

Expression profiles

Bgee: expression breadth ubiquitous, 262 present calls, max score 98.22.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 46.2193 / max 832.8301, expressed in 1805 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
135223	44.1552	1801
135226	0.9631	563
135227	0.5940	279
135224	0.3873	191
135225	0.1197	33

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	98.22	gold quality
ganglionic eminence	UBERON:0004023	95.70	gold quality
embryo	UBERON:0000922	94.44	gold quality
oocyte	CL:0000023	94.32	gold quality
secondary oocyte	CL:0000655	94.04	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	93.16	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	92.76	gold quality
bone marrow	UBERON:0002371	88.88	gold quality
trabecular bone tissue	UBERON:0002483	87.86	gold quality
monocyte	CL:0000576	87.00	gold quality
bone marrow cell	CL:0002092	86.90	gold quality
mononuclear cell	CL:0000842	86.86	gold quality
testis	UBERON:0000473	86.72	gold quality
hair follicle	UBERON:0002073	86.57	gold quality
right testis	UBERON:0004534	86.31	gold quality
leukocyte	CL:0000738	86.26	gold quality
stromal cell of endometrium	CL:0002255	86.22	gold quality
left testis	UBERON:0004533	86.09	gold quality
esophagus squamous epithelium	UBERON:0006920	85.74	gold quality
endothelial cell	CL:0000115	85.47	gold quality
adrenal tissue	UBERON:0018303	85.25	gold quality
esophagus mucosa	UBERON:0002469	82.77	gold quality
epithelium of esophagus	UBERON:0001976	82.43	gold quality
rectum	UBERON:0001052	82.34	gold quality
cerebellar hemisphere	UBERON:0002245	81.66	gold quality
cerebellar cortex	UBERON:0002129	81.65	gold quality
lymph node	UBERON:0000029	81.17	gold quality
germinal epithelium of ovary	UBERON:0001304	80.95	gold quality
squamous epithelium	UBERON:0006914	80.78	gold quality
tonsil	UBERON:0002372	80.72	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.39

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RARB, TP53

miRNA regulators (miRDB)

86 targeting CKAP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-200A-5P	99.76	69.10	949
HSA-MIR-200B-5P	99.76	69.05	948
HSA-MIR-4306	99.72	70.50	3630

Literature-anchored findings (GeneRIF, showing 20)

• CKAP2 comprises nine exons ranging 70-1442 bp and is about 22 kb in size (regulatory regions included). The CKAP2 promoter contains CCAAT (-39…-33) rather than the canonical TATA box, and harbors nine binding sites for six transcription factors (PMID:12500535)
• protein is expressed cell cycle dependently and it is involved in cell proliferation (PMID:16876122)
• Data show that degradation of TMAP/CKAP2 during mitotic exit is mediated by the anaphase-promoting complex bound to Cdh1 and that the KEN box motif near the N terminus is necessary for its destruction. (PMID:17339342)
• CKAP2 is a physiological substrate of anaphase-promoting complex/cyclosome during mitotic exit and that a tight regulation of the CKAP2 protein level is critical for the normal mitotic progression. (PMID:17376772)
• Cdk1-cyclin B1-mediated phosphorylation of TMAP is important for and contributes to proper regulation of microtubule dynamics and establishment of functional bipolar spindles during mitosis (PMID:19369249)
• TMAP is limited to pre-anaphase stages and suggest that the multiple phosphorylation may not act in concert but serve diverse functions. (PMID:19641375)
• Findings suggest that the motif surrounding Ser627 ((625) RRSRRL (630)) is a critical for kinase-substrate recognition and for regulation of the subcellular localization of TMAP during mitosis. (PMID:20458174)
• GC box was responsible for the cyclic activity of human CKAP2 promoter through the phosphorylation of Sp1, possibly by Cyclin A/Cdk complex. (PMID:22465120)
• CKAP2 is involved in the maintenance of microtubule nucleation sites (PMID:23737987)
• expression might be a potential biologic marker for identifying hepatocellular carcinoma patients at risk of early and extensive recurrence after operative resection (PMID:24238125)
• The transcriptional activity of RHOA, SEMA3B, and CKAP2 genes was assessed in blood samples of leukaemia patients and healthy donors. (PMID:24280143)
• Chromatin CKAP2 is an independent prognostic marker for relapse-free survival in early-stage breast cancer, and could potentially replace the mitotic activity index in clinical evaluation of proliferation activity. (PMID:24887265)
• CKAP2 acts as a functional oncogene in cervical carcinoma development and may exert its function by targeting FAK-ERK2 signaling pathway. (PMID:28522860)
• High CKAP2 expression is associated with Ovarian Cancer. (PMID:28933561)
• High CKAP2 expression is associated with highgrade glioma. (PMID:30066946)
• Knockdown of CKAP2 expression effectively suppressed the proliferation and induced the apoptosis by inhibiting the phosphorylation of JAK2/STAT3 of osteosarcoma cells. (PMID:30119212)
• Cytoskeleton-associated protein 2 (CKAP2) is regulated by vascular endothelial growth factor and p53 in retinal capillary endothelial cells under high-glucose conditions. (PMID:34216644)
• LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis. (PMID:34596006)
• Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1alpha-induced transcription of CKAP2. (PMID:35853854)
• CKAP2 overexpression correlates with worse overall survival in patients with lung adenocarcinoma. (PMID:35905213)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-266i6.3	ENSDARG00000086112
mus_musculus	Ckap2	ENSMUSG00000037725
rattus_norvegicus	Ckap2	ENSRNOG00000024650

Paralogs (1): CKAP2L (ENSG00000169607)

Protein

Protein identifiers

Cytoskeleton-associated protein 2 — Q8WWK9 (reviewed: Q8WWK9)

Alternative names: CTCL tumor antigen se20-10, Tumor- and microtubule-associated protein

All UniProt accessions (3): C9J649, C9J7Y4, Q8WWK9

UniProt curated annotations — full annotation on UniProt →

Function. Possesses microtubule stabilizing properties. Involved in regulating aneuploidy, cell cycling, and cell death in a p53/TP53-dependent manner.

Subunit / interactions. Associates with alpha- and beta-tubulins.

Subcellular location. Cytoplasm. Cytoskeleton. Spindle. Spindle pole.

Tissue specificity. Abundant in testis, thymus, and in tumor derived cell lines, while barely detectable in liver, prostate, and kidney.

Induction. Up-regulated in primary human gastric cancers.

Similarity. Belongs to the CKAP2 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8WWK9-1	1	yes
Q8WWK9-4	2
Q8WWK9-6	4
Q8WWK9-5	3

RefSeq proteins (4): NP_001091995, NP_001273615, NP_001273616, NP_060674* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026165	CKAP2_fam	Family
IPR029197	CKAP2_C	Domain

Pfam: PF15297

UniProt features (30 total): modified residue 10, sequence conflict 6, region of interest 4, splice variant 4, compositionally biased region 3, sequence variant 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WWK9-F1	59.29	0.10

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (10): 534, 579, 582, 595, 596, 597, 599, 602, 178, 190

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 269 (showing top): GOBP_MITOTIC_CYTOKINESIS, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, HORIUCHI_WTAP_TARGETS_DN, GNF2_CENPF, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, MITSIADES_RESPONSE_TO_APLIDIN_DN, GOCC_MICROTUBULE_ORGANIZING_CENTER, SHEPARD_BMYB_MORPHOLINO_DN, GOLDRATH_ANTIGEN_RESPONSE, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_MICROTUBULE_DEPOLYMERIZATION, GOBP_CYTOKINESIS

GO Biological Process (4): mitotic cytokinesis (GO:0000281), apoptotic process (GO:0006915), negative regulation of microtubule depolymerization (GO:0007026), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (0):

GO Cellular Component (11): spindle pole (GO:0000922), nucleolus (GO:0005730), centrosome (GO:0005813), microtubule (GO:0005874), cilium (GO:0005929), microtubule cytoskeleton (GO:0015630), ciliary basal body (GO:0036064), mitotic spindle (GO:0072686), cytoplasm (GO:0005737), spindle (GO:0005819), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membraneless organelle	3
spindle	2
cellular anatomical structure	2
microtubule organizing center	2
microtubule cytoskeleton	2
mitotic cell cycle	1
cytoskeleton-dependent cytokinesis	1
mitotic cell cycle process	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
microtubule depolymerization	1
negative regulation of microtubule polymerization or depolymerization	1
regulation of microtubule depolymerization	1
negative regulation of protein depolymerization	1
negative regulation of supramolecular fiber organization	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
nuclear lumen	1
centriole	1
polymeric cytoskeletal fiber	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1
cytoskeleton	1
cilium	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1370 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CKAP2	CDKN1B	P46527	562
CKAP2	GAS2L3	Q86XJ1	552
CKAP2	BUB1	O43683	545
CKAP2	LMNB1	P20700	530
CKAP2	BIRC5	O15392	528
CKAP2	CEP55	Q53EZ4	517
CKAP2	CDK1	P06493	515
CKAP2	BUB1B	O60566	513
CKAP2	NEK2	P51955	489
CKAP2	PIMREG	Q9BSJ6	488
CKAP2	GRM1	Q13255	484
CKAP2	RACGAP1	Q9H0H5	483
CKAP2	G2E3	Q7L622	476
CKAP2	CKAP5	Q14008	471
CKAP2	GFAP	P14136	455

IntAct

89 interactions, top by confidence:

A	B	Type	Score
MED20	MED19	psi-mi:“MI:0914”(association)	0.840
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
CEP170	KIF2A	psi-mi:“MI:2364”(proximity)	0.650
CEP104	CCDC66	psi-mi:“MI:2364”(proximity)	0.540
MIS12	SPC24	psi-mi:“MI:0914”(association)	0.530
TRAK2	OGT	psi-mi:“MI:0914”(association)	0.530
TMEM171	THAP12	psi-mi:“MI:0914”(association)	0.530
BAG2	HGS	psi-mi:“MI:0914”(association)	0.530
MAD2L1	PPIP5K2	psi-mi:“MI:0914”(association)	0.530
KIAA0753	OFD1	psi-mi:“MI:2364”(proximity)	0.480
LRRK1	CKAP2	psi-mi:“MI:0407”(direct interaction)	0.440
CEP162	CCP110	psi-mi:“MI:2364”(proximity)	0.420
OTUB1		psi-mi:“MI:0914”(association)	0.350
OTUB1	EPM2A	psi-mi:“MI:0914”(association)	0.350
Srp72		psi-mi:“MI:0914”(association)	0.350
Wdr5	MGA	psi-mi:“MI:0914”(association)	0.350
NCBP3	ALYREF	psi-mi:“MI:0914”(association)	0.350
Tpx2		psi-mi:“MI:0914”(association)	0.350
SLC33A1	METTL8	psi-mi:“MI:0914”(association)	0.350
KIF22	PSEN2	psi-mi:“MI:0914”(association)	0.350
LDHD	METTL8	psi-mi:“MI:0914”(association)	0.350
JUN		psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
IGHA1	PLG	psi-mi:“MI:0914”(association)	0.350
TANK	CNOT1	psi-mi:“MI:0914”(association)	0.350

BioGRID (164): CKAP2 (Affinity Capture-MS), CKAP2 (Affinity Capture-MS), CKAP2 (Affinity Capture-MS), CKAP2 (Proximity Label-MS), CKAP2 (Proximity Label-MS), CKAP2 (Proximity Label-MS), CKAP2 (Affinity Capture-MS), CKAP2 (Proximity Label-MS), CKAP2 (Proximity Label-MS), CKAP2 (Proximity Label-MS), CKAP2 (Proximity Label-MS), CKAP2 (Proximity Label-MS), CKAP2 (Proximity Label-MS), CKAP2 (Proximity Label-MS), CKAP2 (Proximity Label-MS)

ESM2 similar proteins: A0JMZ1, A1L2F3, A1L3I5, A2AG50, A5D7U0, A9C3N6, B7ZD04, E7F568, O13024, O75167, P53352, P86345, P86346, Q0IHP2, Q0P4A6, Q0V9F7, Q10189, Q15398, Q1W1G1, Q24595, Q2YDJ0, Q32N93, Q3KPK4, Q3KQW7, Q4V7H8, Q563C3, Q5BKG8, Q5R1T0, Q5R7F8, Q5SPR8, Q5XG21, Q5XLR4, Q5ZJU5, Q6CNI5, Q6GLC7, Q7K3L1, Q7TS74, Q801E2, Q8IYA6, Q8K298

Diamond homologs: A5D7U0, Q3V1H1, Q5R7F8, Q8WWK9, A5PK21, Q8IYA6, Q7TS74

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
AURKB	up-regulates	CKAP2	phosphorylation
CDK1	up-regulates	CKAP2	phosphorylation
CyclinB/CDK1	up-regulates	CKAP2	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 110 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Loss of Nlp from mitotic centrosomes	9	20.1×	8e-08
Loss of proteins required for interphase microtubule organization from the centrosome	9	20.1×	8e-08
AURKA Activation by TPX2	9	19.3×	8e-08
Recruitment of mitotic centrosome proteins and complexes	9	17.2×	2e-07
Recruitment of NuMA to mitotic centrosomes	10	16.4×	8e-08
Regulation of PLK1 Activity at G2/M Transition	9	16.1×	3e-07
Anchoring of the basal body to the plasma membrane	10	15.9×	8e-08
Amplification of signal from the kinetochores	5	13.9×	1e-03

GO biological processes:

GO term	Partners	Fold	FDR
non-motile cilium assembly	5	15.1×	4e-03
cilium assembly	9	6.9×	2e-03
cell division	13	6.2×	1e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

105 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	87
Likely benign	9
Benign	5

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3024581	GRCh37/hg19 13q13.2-21.2(chr13:34884647-61309742)x1	Pathogenic

SpliceAI

1570 predictions. Top by Δscore:

Variant	Effect	Δscore
13:52455622:CAAAG:C	donor_loss	1.0000
13:52455623:AAAG:A	donor_loss	1.0000
13:52455626:GGTGA:G	donor_loss	1.0000
13:52455627:G:GA	donor_loss	1.0000
13:52456521:A:AG	acceptor_gain	1.0000
13:52456521:AGAG:A	acceptor_loss	1.0000
13:52456522:G:GA	acceptor_gain	1.0000
13:52456522:GA:G	acceptor_gain	1.0000
13:52456522:GAGC:G	acceptor_gain	1.0000
13:52456607:GGTAA:G	donor_loss	1.0000
13:52456608:G:GG	donor_gain	1.0000
13:52456609:T:G	donor_loss	1.0000
13:52460894:A:G	acceptor_gain	1.0000
13:52460895:G:GG	acceptor_gain	1.0000
13:52460895:GTA:G	acceptor_gain	1.0000
13:52461925:AA:A	donor_gain	1.0000
13:52461926:AG:A	donor_loss	1.0000
13:52461927:G:GG	donor_gain	1.0000
13:52462526:G:GG	donor_gain	1.0000
13:52463714:GGA:G	donor_gain	1.0000
13:52465292:TAG:T	acceptor_loss	1.0000
13:52465293:A:AG	acceptor_gain	1.0000
13:52465293:A:C	acceptor_loss	1.0000
13:52465293:AG:A	acceptor_gain	1.0000
13:52465293:AGG:A	acceptor_gain	1.0000
13:52465294:G:A	acceptor_gain	1.0000
13:52465294:G:GA	acceptor_gain	1.0000
13:52465294:GGG:G	acceptor_gain	1.0000
13:52465294:GGGA:G	acceptor_gain	1.0000
13:52465294:GGGAT:G	acceptor_gain	1.0000

AlphaMissense

4511 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:52474967:A:C	R626S	0.994
13:52474967:A:T	R626S	0.994
13:52474966:G:C	R626T	0.990
13:52465445:G:C	A487P	0.989
13:52465376:T:A	W464R	0.988
13:52465376:T:C	W464R	0.988
13:52475014:T:C	L642S	0.987
13:52465446:C:A	A487D	0.983
13:52474965:A:G	R626G	0.982
13:52465335:T:C	L450P	0.980
13:52474954:T:C	L622S	0.979
13:52465382:T:C	C466R	0.978
13:52465461:C:A	A492D	0.977
13:52475053:T:C	L655P	0.977
13:52465373:T:G	Y463D	0.976
13:52468294:G:C	R499P	0.976
13:52474971:T:C	S628P	0.976
13:52474977:C:A	R630S	0.976
13:52474951:T:C	F621S	0.975
13:52474978:G:C	R630P	0.975
13:52474968:C:A	R627S	0.974
13:52474960:C:A	P624Q	0.973
13:52475082:T:C	F665L	0.973
13:52475084:T:A	F665L	0.973
13:52475084:T:G	F665L	0.973
13:52474969:G:C	R627P	0.970
13:52465326:T:C	L447P	0.969
13:52474966:G:T	R626I	0.969
13:52465378:G:C	W464C	0.967
13:52465378:G:T	W464C	0.967

dbSNP variants (sampled 300 via entrez): RS1000100365 (13:52463404 C>T), RS1000320568 (13:52472450 T>C), RS1000594134 (13:52455775 C>G,T), RS1000835057 (13:52463831 T>A), RS1000837991 (13:52473322 A>G), RS1000979529 (13:52467249 A>G), RS1000989313 (13:52457505 T>C), RS1001026901 (13:52455937 C>G,T), RS1001219786 (13:52466796 C>T), RS1001289500 (13:52457341 T>C,G), RS1001321504 (13:52460535 C>G,T), RS1001377775 (13:52456894 A>T), RS1001451698 (13:52467598 A>G), RS1001507093 (13:52473580 G>A,C), RS1001651360 (13:52466955 T>A,C,G)

Disease associations

OMIM: gene MIM:611569 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

61 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	5
Cyclosporine	decreases expression	4
bisphenol A	decreases expression, affects expression	2
sodium arsenite	decreases expression, increases expression	2
Resveratrol	affects cotreatment, increases expression	2
Doxorubicin	affects response to substance, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Plant Extracts	affects cotreatment, increases expression, decreases expression	2
Aflatoxin B1	affects expression, decreases methylation	2
Cadmium Chloride	decreases expression, decreases methylation, increases expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
dicrotophos	decreases expression	1
testosterone enanthate	affects expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
deoxynivalenol	increases expression	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	decreases methylation	1
cupric oxide	decreases expression	1
diallyl trisulfide	decreases expression	1
beta-methylcholine	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
2-palmitoylglycerol	increases expression	1
K 7174	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7MM	Ubigene A-549 CKAP2 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.